Publications

• Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores
  Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., Nadler, J., … Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050–56.
• Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
  Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV Therapy, 13(2), 36–39.
• Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
  Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., Farthing, C., … Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680–82.
• Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS Reports, 6(2), 63–67.
  
• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., Cain, P., … Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305–8.
  
• The use of resistance testing in the management of HIV-1-infected patients Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474–80.
  
• International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., Wirden, M., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520–25.
  
• Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., Charest, H., … Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473–2479.
  
• Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., Lederman, M. M., … Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7).
  
• Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901–10.
  
• Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984–985.
  
• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211–20.
  
• When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Grant, P. M., & Zolopa, A. R. (2012). When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now! Current HIV/AIDS Reports, 9(3), 251–58.
  
• Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164 Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., Andersen, J., … Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715–23.
  
• Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164 Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., Zolopa, A. R., … Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248–259.
  
• Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., Scully, E., … Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197–202.
  
• Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., … Brown, T. T. (2013). Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. Clinical Infectious Diseases , 57(10), 1483–88.
  
• TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY Talbot, A., Uwihoreye, C., Kamen, C., Grant, P., McGlynn, L., Mugabe, I., … Zolopa, A. (2013). TREATING PSYCHOLOGICAL TRAUMA AMONG RWANDAN ORPHANS IS ASSOCIATED WITH A REDUCTION IN HIV RISK-TAKING BEHAVIORS: A PILOT STUDY. AIDS EDUCATION AND PREVENTION, 25(6), 468–79.
  
• Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202 Grant, P. M., Tierney, C., Budhathoki, C., Daar, E. S., Sax, P. E., Collier, A. C., … Katzenstein, D. (2013). Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV CLINICAL TRIALS, 14(6), 284–91.
  
• Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-?
  
• Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations Richardson, E. T., Grant, P. M., & Zolopa, A. R. (2014). Evolution of HIV treatment guidelines in high- and low-income countries: Converging recommendations. ANTIVIRAL RESEARCH, 103, 88–93.
  
• Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. Liang, E. C., Sceats, L., Bayless, N. L., Strauss-Albee, D. M., Kubo, J., Grant, P. M., … Blish, C. A. (2014). Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults. Journal of Virology, 88(15), 8629–39.
  
• Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. Alistar, S. S., Grant, P. M., & Bendavid, E. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12, 46-?
  
• Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164 Grant, P. M., Komarow, L., Sanchez, A., Sattler, F. R., Asmuth, D. M., Pollard, R. B., & Zolopal, A. R. (2014). Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV CLINICAL TRIALS, 15(4), 133–39.
  
• Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga. Nelson, J., Waggoner, J. J., Sahoo, M. K., Grant, P. M., & Pinsky, B. A. (2014). Encephalitis caused by chikungunya virus in a traveler from the kingdom of tonga. Journal of Clinical Microbiology, 52(9), 3459–61.
  
• Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen Lee, A. J., Bosch, R. J., Evans, S. R., Wu, K., Harrison, T., Grant, P., & Clifford, D. B. (2015). Patterns of peripheral neuropathy in ART-na < ve patients initiating modern ART regimen. JOURNAL OF NEUROVIROLOGY, 21(2), 210–18.
  
• Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults Grant, P. M., Kitch, D., McComsey, G. A., Tierney, C., Ha, B., & Brown, T. T. (2015). Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV CLINICAL TRIALS, 16(2), 66–71.
  
• Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Case Report: Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid versus Serum or Plasma. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 93(2), 238–40.
  
• Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma. Waggoner, J. J., Soda, E. A., Seibert, R., Grant, P., & Pinsky, B. A. (2015). Molecular Detection of Leptospira in Two Returned Travelers: Higher Bacterial Load in Cerebrospinal Fluid Versus Serum or Plasma. American Journal of Tropical Medicine and Hygiene, 93(2), 238–40.
  
• Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. DRUGS, 76(1), 75–98.
  
• Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients Grant, P. M., Sheikh, V., DerSimonian, R., Rupert, A., Roby, G., Pau, A., … Sereti, I. (2015). Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(7), 739–44.
  
• Tenofovir and bone health Grant, P. M., & Cotter, A. G. (2016). Tenofovir and bone health. CURRENT OPINION IN HIV AND AIDS, 11(3), 326–32.
  
• When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now! Grant, P. M., & Zolopa, A. R. (2012). When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now! CURRENT HIV/AIDS REPORTS, 9(3), 251–258.
  
• Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Koletar, S. L., Erlandson, K. M., … Brown, T. T. (2016). Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. JOURNAL OF INFECTIOUS DISEASES, 214(4), 607–11.
  
• A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Collins, S. E., Grant, P. M., Uwinkindi, F., Talbot, A., Seruyange, E., Slamowitz, D., … Nsanzimana, S. (2016). A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans. Open Forum Infectious Diseases, 3(3), ofw141-?
  
• Long-term body composition changes in antiretroviral-treated HIV-infected individuals Grant, P. M., Kitch, D., McComsey, G. A., Collier, A. C., Bartali, B., Koletar, S. L., … Brown, T. T. (2016). Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS, 30(18), 2805–13.
  
• Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. Paredes, R., Tzou, P. L., van Zyl, G., Barrow, G., Camacho, R., Carmona, S., … Shafer, R. W. (2017). Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PloS One, 12(7), e0181357.
  
• High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study Gupta, N., Kabahizi, J., Muvunyi, C., Mbituyumuremyi, A., Van Nuil, J. I., & Grant, P. M. (2017). High Rates of Rapid Virologic Response for Chronic Hepatitis C Infection Treated with Ledipasvir/Sofosbuvir in Rwanda: Preliminary Results from the SHARED Study. HEPATOLOGY, 66, 615A.
  
• Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men. Grant, P. M., Li, X., Jacobson, L., Palella, F. J., Kingsley, L., Margolick, J. B., … Brown, T. (2018). Effect of Testosterone Use on Bone Mineral Density in HIV-infected Men. AIDS Research and Human Retroviruses.
  
• Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study Grant, P., Kabahizi, J., Mbituyumuremyi, A., Van Nuil, J. I., Mukabatsinda, C., Damascene, M. J., … Gupta, N. (2018). Safety and Efficacy of Ledipasvir/Sofosbuvir without on-Treatment Laboratory Monitoring in HCV-Infected Rwandans: The Shared 2 Study. HEPATOLOGY, 68, 36A.
  
• A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. Mellor-Crummey, L. E., Lake, J. E., Wilhalme, H., Tseng, C.-H., Grant, P. M., Erlandson, K. M., … Brown, T. T. (2018). A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. Journal of Clinical Gastroenterology and Hepatology, 2(3).
  
• Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Gupta, N., Mbituyumuremyi, A., Kabahizi, J., Ntaganda, F., Muvunyi, C. M., Shumbusho, F., … Grant, P. M. (2018). Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. The Lancet. Gastroenterology & Hepatology.
  
• Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Collins, S. E., Grant, P. M., & Shafer, R. W. (2016). Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs, 76(1), 75–98.
  
• Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men Grant, P. M., Li, X., Jacobson, L. P., Palella, F. J., Kingsley, L. A., Margolick, J. B., … Brown, T. T. (2019). Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men. AIDS RESEARCH AND HUMAN RETROVIRUSES, 35(1), 75–80.
  
• A systematic review of the genetic mechanisms of dolutegravir resistance. Rhee, S.-Y. Y., Grant, P. M., Tzou, P. L., Barrow, G., Harrigan, P. R., Ioannidis, J. P., & Shafer, R. W. (2019). A systematic review of the genetic mechanisms of dolutegravir resistance. The Journal of Antimicrobial Chemotherapy.
  
• Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. HEPATOLOGY COMMUNICATIONS.
  
• Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Grant, P., Shumbusho, F., Van Nuil, J. I., Kateera, F., Mukherjee, J., Kabahizi, J., … Gupta, N. (2020). Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda. Hepatology Communications, 4(4), 569–76.
  
• Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. Ramadoss, N. S., Zhao, N. Q., Richardson, B. A., Grant, P. M., Kim, P. S., & Blish, C. A. (2020). Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. AIDS (London, England).
  
• Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. Goldman, J. D., Lye, D. C., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., … Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine.
  
• Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells. Zhao, N. Q., Ferreira, A.-M., Grant, P. M., Holmes, S., & Blish, C. A. (2020). Treated HIV Infection Alters Phenotype but Not HIV-Specific Function of Peripheral Blood Natural Killer Cells. Frontiers in Immunology, 11, 829.
  
• A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martinez-Colon, G. J., McKechnie, J. L., … Blish, C. A. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature Medicine.
  
• Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J. A., Asuni, A., … Rogers, A. J. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight.
  
• Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. Igbinosa, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., … Aziz, N. (2020). Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. American Journal of Obstetrics and Gynecology.
  
• Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study). Van Nuil, J. I., Umutesi, G., Shumbusho, F., Kateera, F., Dushimimana, J. de D., Muvunyi, C. M., … Gupta, N. (2020). Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study). Journal of Viral Hepatitis.
  
• Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa. Shumbusho, F., Liu, A. F., Kateera, F., Kabahizi, J., Nsanzaimana, S., Serumondo, J., … Gupta, N. (2021). Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa. Journal of Viral Hepatitis.